Biomerica, Inc. (BMRA) Financial Statements (2024 and earlier)

Company Profile

Business Address 17571 VON KARMAN AVENUE
IRVINE, CA 92614
State of Incorp. DE
Fiscal Year End May 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

8/31/2023
Q1
5/31/2023
Q4
2/28/2023
Q3
11/30/2022
Q2
8/31/2022
Q1
5/31/2022
Q4
2/28/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,7193,3455,0676,0755,91710,174
Cash and cash equivalents9,7193,3455,0676,0755,91710,174
Receivables7227558509327741,139
Inventory, net of allowances, customer advances and progress billings2,0562,0642,0611,9222,4163,231
Inventory2,0562,0642,0611,9222,4163,231
Other undisclosed current assets300318121239320687
Total current assets:12,7976,4828,0999,1689,42815,231
Noncurrent Assets
Operating lease, right-of-use asset1,0351,1021,1691,2351,3021,368
Property, plant and equipment213228237228214263
Intangible assets, net (including goodwill)165155158161170386
Intangible assets, net (excluding goodwill)165155158161170386
Other noncurrent assets7979809496147
Other undisclosed noncurrent assets165165165165165165
Total noncurrent assets:1,6571,7281,8091,8821,9472,329
TOTAL ASSETS:14,4548,2109,90811,05011,37417,560
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8923876706719722,609
Accounts payable 344   736 
Accrued liabilities548520697 236 
Other undisclosed accounts payable and accrued liabilities (133)(27)67102,609
Other undisclosed current liabilities1,0531,0081,0931,0861,0394,089
Total current liabilities:1,9451,3951,7631,7582,0116,698
Noncurrent Liabilities
Long-term debt and lease obligation:    9711,0381,105
Liabilities, other than long-term debt785829901   
Operating lease, liability7858299019711,0381,105
Other undisclosed noncurrent liabilities    (971)(1,038)(1,105)
Total noncurrent liabilities:785829901971 1,105
Total liabilities:2,7302,2242,6652,7283,0507,803
Equity
Equity, attributable to parent11,7245,9867,2438,3228,3259,758
Common stock1,3461,0791,0781,0731,0291,028
Additional paid in capital52,70545,44345,03544,48542,44742,109
Accumulated other comprehensive loss(110)(111)(95)(86)(74)(61)
Accumulated deficit(42,217)(40,425)(38,775)(37,149)(35,077)(33,318)
Total equity:11,7245,9867,2438,3228,3259,758
TOTAL LIABILITIES AND EQUITY:14,4548,2109,90811,05011,37417,560

Income Statement (P&L) ($ in thousands)

8/31/2023
Q1
5/31/2023
Q4
2/28/2023
Q3
11/30/2022
Q2
8/31/2022
Q1
5/31/2022
Q4
2/28/2022
Q3
Revenues1,1081,1111,4821,6375,3027,661
Cost of revenue(1,079)(991)(1,130)(1,692)(4,681)(5,987)
Gross profit:29120352(55)6211,673
Operating expenses(1,865)(1,771)(2,018)(2,015)(2,378)(1,781)
Operating loss:(1,836)(1,651)(1,666)(2,070)(1,756)(107)
Nonoperating income573641076
Investment income, nonoperating  3641076
Loss from continuing operations before income taxes:(1,779)(1,615)(1,625)(2,070)(1,749)(101)
Income tax expense(13)(35)(1)(2)(10)(3)
Loss from continuing operations:(1,792)(1,650)(1,626)(2,072)(1,759)(104)
Loss before gain (loss) on sale of properties:(2,072)(1,759)(104)
Net loss available to common stockholders, diluted:(1,792)(1,650)(1,626)(2,072)(1,759)(104)

Comprehensive Income ($ in thousands)

8/31/2023
Q1
5/31/2023
Q4
2/28/2023
Q3
11/30/2022
Q2
8/31/2022
Q1
5/31/2022
Q4
2/28/2022
Q3
Net loss:(1,792)(1,650)(1,626)(2,072)(1,759)(104)
Comprehensive loss:(1,792)(1,650)(1,626)(2,072)(1,759)(104)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(15)(9)(13)(13)(3)
Comprehensive loss, net of tax, attributable to parent:(1,791)(1,665)(1,635)(2,084)(1,772)(107)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: